The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Regulatory T-cell Depletion Alters the Tumor Microenvironment and Accelerates Pancreatic Carcinogenesis
Open accessPublished version of a preprint
Abstract
Regulatory T cells (Treg) are abundant in human and mouse pancreatic cancer. To understand the contribution to the immunosuppressive microenvironment, we depleted Tregs in a mouse model of pancreatic cancer. Contrary to our expectations, Treg depletion failed to relieve immunosuppression and led to accelerated tumor progression. We show that Tregs are a key source of TGFβ ligands and, accordingly, their depletion reprogramed the fibroblast population, with loss of tumor-restraining, smooth muscle actin–expressing fibroblasts. Conversely, we observed an increase in chemokines Ccl3, Ccl6, and Ccl8 leading to increased myeloid cell recruitment, restoration of immune suppression, and promotion of carcinogenesis, an effect that was inhibited by blockade of the common CCL3/6/8 receptor CCR1. Further, Treg depletion unleashed pathologic CD4+ T-cell responses. Our data point to new mechanisms regulating fibroblast differentiation in pancreatic cancer and support the notion that fibroblasts are a heterogeneous population with different and opposing functions in pancreatic carcinogenesis. Significance: Here, we describe an unexpected cross-talk between Tregs and fibroblasts in pancreatic cancer. Treg depletion resulted in differentiation of inflammatory fibroblast subsets, in turn driving infiltration of myeloid cells through CCR1, thus uncovering a potentially new therapeutic approach to relieve immunosuppression in pancreatic cancer. See related commentary by Aykut et al., p. 345. This article is highlighted in the In This Issue feature, p. 327
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, this study analyzed tissue levels and found that the positive effect of Tregs depletion, which results in an increase in CD8+ T cells, was negated by an increase in other CD4+ Th cells, immunosuppressive myeloid cells, and fibroblast populations, ultimately failing to inhibit tumor growth [116, 131] (Fig. 2E).”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [116]
Experimental — accuracy not yet measuredIn the citing paper
“Other T cell populations within the TME have all been noted to play protumorigenic roles, including Th17, Th22, CD4, and γδ T cells188–191”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature reviews. Immunology · doi:10.1038/nri2785 · Cited by 2,524
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Cited by
Sorted by citations
Items 201–300 of 389
Regulatory T Cells Keep Pancreatic Cancer at Bay
Aykut, B., Chen, R., & Miller, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0002 · Cited by 11
Schoonderwoerd, M. J. A., Hakuno, S. K., Sassen, M., Kuhlemaijer, E. B., Paauwe, M., Slingerland, M., Fransen, M. F., & Hawinkels, L. J. A. C. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s322276 · Cited by 11
Hom, L. M., Sun, S., Campbell, J., Liu, P., Culbert, S., Murphy, I. M., & Schafer, Z. T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104922 · Cited by 11
Tang, S., Shi, L., Luker, B. T., Mickler, C., Suresh, B., Lesinski, G. B., Fan, D., Liu, Y., & Luo, M. (2022) · Virology Journal · doi:10.1186/s12985-022-01757-7 · Cited by 11
An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer
Huang, J., Wang, M., Zhang, F., Shao, S., Yao, Z., Zhao, X., Hu, Q., & Liang, T. (2023) · Advanced Science · doi:10.1002/advs.202206756 · Cited by 11
Zhang, Y., Du, Y., Wang, J., Wang, D., Li, J., Zhang, J., Zhao, Y., Sun, S., Sun, H., Qi, J., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2025.09.043 · Cited by 10
Self-citationSong, L., Wang, B., Cai, J., Zhang, P., Chen, S., Zhou, Z., & Dai, Z. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02463-z · Cited by 10
Targeting the pancreatic tumor microenvironment by plant-derived products and their nanoformulations
Saadh, M. J., Mustafa, M. A., Malathi, H., Ahluwalia, G., Kaur, S., Al-Dulaimi, M. A. A. H., Alubiady, M. H. S., Al‐Abdeen, S. H. Z., Shakier, H. G., Ali, M. S., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02443-0 · Cited by 10
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma
Li, X., Hou, W., Xiao, C., Yang, H., Zhao, C., & Cao, D. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00970-6 · Cited by 10
Dai, S., Peng, Y., Wang, G., Chen, C., Chen, Q., Yin, L., Yan, H., Zhang, K., Tu, M., Lu, Z., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01358-7 · Cited by 11
Liu, Y., Qiao, S., Zhang, G., Lü, A., & Li, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010991 · Cited by 10
Kashkooli, F. M., Mirala, F., Tehrani, M. H. H., Alirahimi, M., Souri, M., Golzaryan, A., Kar, S., & Soltani, M. (2025) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.70000 · Cited by 12
Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
Ahmed, A., Klotz, R., Köhler, S., Giese, N. A., Hackert, T., Springfeld, C., Jäger, D., & Halama, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947407 · Cited by 10
CENPA acts as a prognostic factor that relates to immune infiltrates in gliomas
Wang, B., Wei, W., Long, S., Wang, L., Yang, B., Wu, D., Li, Z., Li, X., Arshad, M., Li, X., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1015221 · Cited by 10
Sun, Y., Yao, L., Man, C., Gao, Z., He, R. L., & Fan, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220760 · Cited by 11
Alqahtani, M. F., Aljuaimlani, A., Al‐Tamimi, J., Alomar, S. Y., & Mansour, L. A. (2024) · Hematology · doi:10.1080/16078454.2024.2329024 · Cited by 10
Xu, P., Cheng, C., Dong, S., Wang, T., Xie, J., & Li, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10597-9 · Cited by 9
Cellular crosstalk of regulatory T cells in pancreatic ductal adenocarcinoma
Shi, X., Liu, H., & Liang, Z. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000135 · Cited by 10
Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation
Opsahl, E. L. L., Espinoza, C. E., Olivei, A. C., Okoye, J. O., Watkoske, H. R., Hoffman, M. T., Avritt, F. R., Elhossiny, A. M., Bischoff, A. C., Donahue, K. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-3472 · Cited by 9
Self-citationDeciphering the liver’s role in pancreatic cancer metastasis: pathways and therapeutic approaches
Inzunza, J., & del Valle, A. C. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01202-2 · Cited by 11
Sun, D., Dai, T., Ji, Y., Shen, W., & Bian, W. (2023) · Cell Biology International · doi:10.1002/cbin.12009 · Cited by 9
Palma, A. M., Vudatha, V., Peixoto, M. L., & Madan, E. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.02.005 · Cited by 10
Pu, Y., Yang, G., Zhou, Y., Pan, X., Guo, T., & Chai, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112198 · Cited by 9
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Musiu, C., Lupo, F., Agostini, A., Lionetto, G., Bevere, M., Paiella, S., Carbone, C., Corbo, V., Ugel, S., & Sanctis, F. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341079 · Cited by 9
Zhou, Q., Chen, D., Zhang, J., Xiang, J.-F., Zhang, T., Wang, H., & Zhang, Y. (2022) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000109 · Cited by 9
Self-citationDiab, M., & El‐Rayes, B. F. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.60 · Cited by 10
Choi, Y., Ando, Y., Lee, D. H., Kim, N. Y., Lee, E., Cho, J., Seo, I., Chong, G. O., & Park, J. Y. (2023) · Life · doi:10.3390/life13122342 · Cited by 8
Guo, X., Zhang, H., Yao, L., & Ma, W. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105076 · Cited by 9
Regulatory T cells in cancer and inflammation
Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 8
Hu, X., Chen, M., Ruan, Q., Shi, C., Pan, J., & Luo, L. (2022) · Journal of Immunology Research · doi:10.1155/2022/2039447 · Cited by 9
Cancer-associated fibroblasts in acute leukemia
Gu, L., Liao, P. H., & Liu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1022979 · Cited by 8
Zhang, M., Chen, H., Liang, B., Wang, X., Gu, N., Xue, F., Yue, Q., Zhang, Q., & Hong, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.777921 · Cited by 7
Advances in Research on the Effects and Mechanisms of Chemokines and Their Receptors in Cancer
Xu, J., Li, J., Chen, Q., Shestakova, E. A., Misyurin, V. A., Pokrovsky, V. S., Tchevkina, E. M., Chen, H., Song, H., & Zhang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920779 · Cited by 8
Mejia, I., Bodapati, S., Chen, K. T., & Díaz, B. (2020) · Biomedicines · doi:10.3390/biomedicines8100401 · Cited by 9
Srinivasan, D., Gout, J., Kleger, A., & Roger, É. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115697 · Cited by 7
Single Cell RNA Sequencing: A New Frontier in Pancreatic Ductal Adenocarcinoma
Zerdan, M. B., Shatila, M., Sarwal, D., Bouferraa, Y., Zerdan, M. B., Allam, S., Ramovic-Zobic, M., & Graziano, S. L. (2022) · Cancers · doi:10.3390/cancers14194589 · Cited by 7
Kaplon, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835502 · Cited by 6
Li, Y., Pan, L., Mugaanyi, J., Li, H., Li, G., Huang, J., & Dai, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-79619-1 · Cited by 6
Seidel, T., Ohri, N., Glaß, M., Sunami, Y., Müller, L. P., & Kleeff, J. H. (2025) · Cancers · doi:10.3390/cancers17091541 · Cited by 7
Hughes, R., Snook, A. E., & Mueller, A. C. (2022) · Immunotherapy · doi:10.2217/imt-2022-0046 · Cited by 6
MMP11 as a prognostic biomarker correlated with immune infiltrates in pancreatic adenocarcinoma
Fang, Z., Xu, X., Tao, L., Lino-Silva, L. S., & Lü, Y. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-425 · Cited by 6
Sahin, I., Türen, S., Santapuram, P. R., & Şahin, İ. H. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.48 · Cited by 6
Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer
Kadiyala, P., Elhossiny, A. M., & Carpenter, E. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.881871 · Cited by 7
Self-citationJiao, J., Cheng, C., Xu, P., Yang, P., Ruan, L., & Chen, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.947238 · Cited by 6
An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
Zhang, T., Gu, Z., Ni, R., Wang, X., Jiang, Q., & Tao, R. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2812361 · Cited by 6
Huang, H., Lan, C., Wei, Y., Nong, J., Liao, X., Ye, X., Deng, G., Peng, T., & Zhou, X. (2024) · PubMed Central · doi:10.18632/aging.205698 · Cited by 6
Gao, Z., Zhang, Q., Zhang, X., & Song, Y. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221092900 · Cited by 6
Suzuki, K., Kunisada, Y., Miyamura, N., Eikawa, S., de Mendoza, T. H., Mose, E. S., Lu, C., Kuroda, Y., Ruoslahti, E. I., Lowy, A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.24.542137 · Cited by 6
Mouratidis, P., Ferreira, R. C., Anbalagan, S., Chauhan, R., Rivens, I., & ter Haar, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080949 · Cited by 5
Targeting Pin1 to overcome immunosuppressive tumor microenvironment in MSS colorectal cancer
Wang, J., Tang, S., Fan, J., Xiao, H., Wang, S., Xiang, J., Liu, Z., Liu, H., Pei, Z., Jiang, D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677029 · Cited by 5
Zhang, G., Shu, Z., Yu, J. Q., Li, J., Yi, P., Wu, B., Deng, D., Yan, S., Li, Y., Ren, D., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341209 · Cited by 5
Cysneiros, M. A. D. P. C., Cirqueira, M. B., Barbosa, L. D. F., de Oliveira, Ê. C., Morais, L. K., Wastowski, I. J., & Floriano, V. G. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305648 · Cited by 5
Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment
Farhangnia, P., Ghomi, S. M., Mollazadehghomi, S., & Delbandi, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_163 · Cited by 5
Walcheck, M. T., Schwartz, P. B., Carrillo, N. D., Matkowskyj, K. A., Nukaya, M., Bradfield, C. A., & Ronnekleiv‐Kelly, S. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002357 · Cited by 5
Okubo, S., Mezawa, Y., Wang, Z., Acar, A., Ito, Y., Takano, A., Miyagi, Y., Yokose, T., Yamashita, T., Daigo, Y., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70074 · Cited by 5
Soto, C. A., Lesch, M. L., Becker, J. D., Sharipol, A., Khan, A. S., Schafer, X., Becker, M. W., Munger, J. C., & Frisch, B. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.13.566874 · Cited by 5
Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma
Kaplan, Z., Prezioso, E., Jain, A., Lavu, H., Yeo, C. J., Bowne, W. B., & Nevler, A. (2025) · Cancer Medicine · doi:10.1002/cam4.70960 · Cited by 4
Suo, D., Liang, L., Xia, Z., Zhang, Y., Zeng, T., Li, S., Guan, X., & Li, Y. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01090-5 · Cited by 4
Self-citationJiang, X., Shang, L., Chen, X., Kong, X., Wang, X., Jiang, L., Zhao, H., Zhu, Y., Huang, C., Deng, S., et al. (2025) · Advanced Science · doi:10.1002/advs.202507159 · Cited by 4
TGF-β1 inhibitor enhances the therapeutic effect of microwave ablation on hepatocellular carcinoma
Xiang, S., Li, J., & Zhang, M. (2024) · International Journal of Hyperthermia · doi:10.1080/02656736.2024.2359496 · Cited by 4
The Role of Tregs in the Tumor Microenvironment
Sato, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13051173 · Cited by 6
Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma
Song, H., & Jiang, C. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2045943 · Cited by 4
Song, Y., Liu, X., Yuan, J., Sha, Z., Jiang, W., Liu, M., Qian, Y., Gao, C., Gong, Z., Luo, H., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.967297 · Cited by 5
Xi, G., Cheng, R.-F., Liang, L., Che, N., Wang, Y., Zhao, N., Liang, X., Shao, B., Zhao, X., & Zhang, D. (2023) · Scientific Reports · doi:10.1038/s41598-023-32692-4 · Cited by 4
Sun, G., Yang, Z., Fang, K., Xiong, Y., Tu, S., Yi, S., & Xiao, W. (2023) · Oncology Letters · doi:10.3892/ol.2023.13847 · Cited by 4
Saris, J., Bootsma, S., Verhoeff, J., Tuynman, J. B., Wildenberg, M. E., Rijnstra, E. S.-V., Lenos, K., García-Vallejo, J. J., Vermeulen, L., & Grootjans, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415457 · Cited by 4
CCR7/DUSP1 signaling Axis mediates iCAF to regulates head and neck squamous cell carcinoma growth
Gao, J., Wang, Z., Lin, S., Tian, Y., Wu, H., Li, Z., & Liu, F. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111305 · Cited by 4
Noncoding Ribonucleic Acids (RNAs) May Improve Response to Immunotherapy in Pancreatic Cancer
Ala, M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00394 · Cited by 4
Wang, R., Liu, J., Jiang, B., Gao, B., Luo, H., Yang, F., Ye, Y., Chen, Z., Liu, H. S., Cui, C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454833 · Cited by 4
Wu, X., Hou, S., Ye, Y., & Gao, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545605 · Cited by 4
Sivakumar, S., Jainarayanan, A., Arbe-Barnes, E. H., Sharma, P. K., Leathlobhair, M. N., Amin, S., Heij, L. R., Hegde, S., Magen, A., Tucci, F. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.31.555730 · Cited by 4
Dhanisha, S. S., Salcedo-Noriega, M. F., Vaish, U., Kannan, A. B., Suryansh, S., Bhandari, S., Chatre, S., Jain, T., Dudeja, V., & Iyer, S. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.01.009 · Cited by 3
Kiemen, A. L., Matos, V., Almagro-Pérez, C., Forjaz, A., Braxton, A. M., Dequiedt, L., Parksong, J., Cannon, C. D., Yuan, X., Shin, S. M., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100008 · Cited by 3
Trieu, V. N., Potts, M., Myers, S., Richardson, S., & Qazi, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125567 · Cited by 3
Regulatory T cells in cancer anti-PD-(L)1 therapy
Mortezaee, K. (2025) · Human Cell · doi:10.1007/s13577-025-01280-1 · Cited by 3
Identification of the Genetic Association Between Type-2-Diabetes and Pancreatic Cancer
Liang, Y., Chen, W., Tang, Y., & Chen, M. (2022) · Biochemical Genetics · doi:10.1007/s10528-022-10308-2 · Cited by 4
Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies
Wang, L., Zhang, W., ZHANG, J., Zheng, M., Pan, X., Guo, H., & Ding, L. (2023) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2023-0263 · Cited by 3
He, J., Li, W., Wang, J., Wu, X., Zhang, W., Lin, J., Xiao, B., Long, Y., Liao, L., Wang, S., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03720-0 · Cited by 3
Carpenter, E. S., Elhossiny, A. M., Kadiyala, P., Li, J., McGue, J. J., Griffith, B. D., Zhang, Y., Edwards, J., Nelson, S., Lima, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.13.523300 · Cited by 3
Self-citationMahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Wang, H., Shalapour, S., Watowich, S. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.05.531191 · Cited by 3
Netrin G1 Ligand is a new stromal immunomodulator that promotes pancreatic cancerPreprint
Costa, D. B. V., Francescone, R., Franco‐Barraza, J., Luong, T., Graves, M., de Aquino, A. M., Steele, N. G., Gardiner, J. C., dos Santos, S. A. A., Ogier, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.15.594354 · Cited by 3
Self-citationTargeting Tregs in pancreatic ductal adenocarcinoma
Siegel, M., Prabhu, A., Hussain, S., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00015-8 · Cited by 2
Wilms Tumor 1–Expressing Stromal Cells Promote Pancreatic Cancer Progression
Bischoff, A. C., Brown, K. L., Lasse-Opsahl, E., Watkoske, H. R., Espinoza, C. E., Okoye, J., Olivei, A., Green, L. M., Rai, R., The, S., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1014
Self-citationRoles of nucleotide metabolism in pancreatic cancer
Liu, Q., Liu, J., Wang, S., Bao, N., Zhao, X., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1637768 · Cited by 2
Role of CCL8 in cancer immunity and tumor progression: Implications for cancer treatment
Jeong, J., & Kim, E. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189502 · Cited by 2
Epithelial FOXP3 Orchestrates O-Glycosylated IL6 Secretion to Drive Pancreatic Fibrocarcinogenesis
Gong, R., Wang, J., Ren, M., Zhang, W., Ping, S., Jing, Y., Lei, K., Yu, Q., Ma, L., Gao, C., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.06.007 · Cited by 2
Li, Y., Zhang, K., Peng, L., Chen, L., Gao, H., & Chen, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810231 · Cited by 2
Management of Advanced Pancreatic Cancer through Stromal Depletion and Immune Modulation
Liu, T., Cheng, S., Xu, Q., & Wang, Z. P. (2022) · Medicina · doi:10.3390/medicina58091298 · Cited by 2
Du, Y., Zhu, L., Li, X., Shi, H., Jiang, W., & Zhou, W. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030433 · Cited by 2
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 2
HRASLS2 promotes the growth and glycolysis of pancreatic cancer by enhancing the stability of ASPH
Ling, Y., Xi, C., Wang, J., Wang, L., Cao, X., & Liu, J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04522-z · Cited by 2
Comprehensive analysis of alternative splicing signatures in pancreatic head cancer
Zhou, L., Yang, Y., Ma, J., Liu, M., Liu, R., Ma, X., & Qiao, C. (2022) · IET Systems Biology · doi:10.1049/syb2.12056 · Cited by 1
Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killingPreprint
Frey, N., Tortola, L., Egli, D., Janjuha, S., Marquart, K. F., Rothgangl, T., Ampenberger, F., Köpf, M., & Schwank, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.29.453937 · Cited by 2
Boucher, Y., Posada, J. M., Subudhi, S., Rosario, S. R., Gu, L., Kumar, A. S., Kumra, H., Mino-Kenudson, M. A., Talele, N. P., Duda, D. G., et al. (2022) · medRxiv · doi:10.1101/2022.06.09.22275912 · Cited by 2
Ex-Vivo 3D Cellular Models of Pancreatic Ductal Adenocarcinoma
Aćimović, I., Gabrielová, V., Martínková, S., Eid, M., Vlažný, J., Moravčík, P., Hlavsa, J., Moráň, L., Cakmakci, R. C., Staňo, P., et al. (2024) · Pancreas · doi:10.1097/mpa.0000000000002393 · Cited by 1
Bednar, F., Olsen, L., & di Magliano, M. P. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-2732 · Cited by 1
Self-citationYuan, S., Hu, T., Yan, L., & Li, M. (2025) · Cancers · doi:10.3390/cancers17182983 · Cited by 1
Huang, Z., Mandelkow, T., Raedler, J. B., Bady, E., Müller, J. H., Simon, R., Vettorazzi, E., Sauter, G., Ebner, J., & Blessin, N. C. (2025) · Laboratory Investigation · doi:10.1016/j.labinv.2025.104248 · Cited by 1
Single-cell sequencing reveals the complexity of cutaneous T-cell lymphoma
Du, J., Yuan, H.-R., Lin, Z., Pan, Y.-E., Zhang, S., Ye, Z., & Lyu, J.-T. (2025) · Discover Oncology · doi:10.1007/s12672-025-04063-0 · Cited by 1
Zhang, J., Zhu, L.-W., Ji, J., Tang, T.-M., Zhu, M.-J., & Yao, H. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.010 · Cited by 2
Metadata
- Authors
- Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H.-J., Nwosu, Z. C., Halbrook, C. J., Menjivar, R. E., Kemp, S. B., Sirihorachai, V. R., Velez-Delgado, A., Donahue, K., Carpenter, E. S., Brown, K. L., Irizarry-Negron, V., Nevison, A. C., Vinta, A., Anderson, M. A., Crawford, H. C., Lyssiotis, C. A., Frankel, T. L., Bednar, F., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- 1Department of Surgery, University of Michigan, Ann Arbor, Michigan.
- Corresponding author
- Zhang, Yaqing
- Bednar, Filip
- ORCID
- Zhang, Yaqing
- Lazarus, Jenny
- Steele, Nina G.
- Yan, Wei
- Lee, Ho-Joon
- Nwosu, Zeribe C.
- Halbrook, Christopher J.
- Menjivar, Rosa E.
- Kemp, Samantha B.
- Sirihorachai, Veerin R.
- Velez-Delgado, Ashley
- Donahue, Katelyn
- Carpenter, Eileen S.
- Brown, Kristee L.
- Irizarry-Negron, Valerie
- Anderson, Michelle A.
- Crawford, Howard C.
- Lyssiotis, Costas A.
- Frankel, Timothy L.
- Bednar, Filip
- Pasca di Magliano, Marina
- Venue
- Cancer Discovery
- Published
- 2020-03-01
- Volume
- 10
- Issue
- 3
- Pages
- 422-439
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7224338
- OpenAlex
- W3000274143
- Cited by
- 385
- References
- 73
- Citations by year
- 2026: 34 · 2025: 49 · 2024: 73 · 2023: 62 · 2022: 66 · 2021: 70 · 2020: 30
- FWCI
- 20.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | NIH | National Cancer Institute (R01CA151588, R01CA198074, U01CA224145, P30CA046592, R50CA232985, 3-P30-CA-046592-28-S2, K08CA201581, T32-CA009676)
- American Cancer Society (Postdoctoral Award)
- University of Michigan Medical School (Michigan Postdoctoral Pioneer Program)
- HHS | NIH | National Institute of General Medical Sciences (T32-GM007315, T32-GM113900)
- Horace H. Rackham School of Graduate Studies, University of Michigan (Rackham Merit Fellowship)
- Association of Academic Surgery (Joel Roslyn Award)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- regulatory T cells, Treg depletion, pancreatic cancer, tumor microenvironment, immunosuppression, TGF-beta, cancer-associated fibroblasts, CCR1, myeloid cell recruitment, CD4+ T cells, pancreatic carcinogenesis, tumor progression
- MeSH terms
- Animals, Disease Models, Animal, Fibroblasts, Humans, Pancreas, Pancreatic Neoplasms, Transforming Growth Factor beta, Chemokines, CC, T-Lymphocytes, Regulatory, Mice, Receptors, CCR1, Chemokine CCL3, Chemokine CCL8, Tumor Microenvironment, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
